| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Maxine Dunitz Neurosurgical Institute and 2 Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California and 3 Department of Experimental Medicine, University of Perugia, Perugia, Italy
Requests for reprints: John S. Yu, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Suite 800 East, 8631 West 3rd Street, Los Angeles, CA 90048. Phone: 310-423-0845; Fax: 310-423-0810; E-mail: yuj{at}cshs.org.
Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in priming immune responses to tumor. Interleukin (IL)-23 can act directly on DC to promote immunogenic presentation of tumor peptide in vitro. Here, we evaluated the combination of bone marrowderived DC and IL-23 on the induction of antitumor immunity in a mouse intracranial glioma model. DCs can be transduced by an adenoviral vector coding single-chain mouse IL-23 to express high levels of bioactive IL-23. Intratumoral implantation of IL-23expressing DCs produced a protective effect on intracranial tumorbearing mice. The mice consequently gained systemic immunity against the same tumor rechallenge. The protective effect of IL-23expressing DCs was comparable with or even better than that of IL-12-expressing DCs. IL-23transduced DC (DC-IL-23) treatment resulted in robust intratumoral CD8+ and CD4+ T-cell infiltration and induced a specific TH1-type response to the tumor in regional lymph nodes and spleen at levels greater than those of nontransduced DCs. Moreover, splenocytes from animals treated with DC-IL-23 showed heightened levels of specific CTL activity. In vivo lymphocyte depletion experiments showed that the antitumor immunity induced by DC-IL-23 was mainly dependent on CD8+ T cells and that CD4+ T cells and natural killer cells were also involved. In summary, i.t. injection of DC-IL-23 resulted in significant and effective systemic antitumor immunity in intracranial tumorbearing mice. These findings suggest a new approach to induce potent tumor-specific immunity to intracranial tumors. This approach may have therapeutic potential for treating human glioma. (Cancer Res 2006; 66(17): 8887-96)
This article has been cited by other articles:
![]() |
G. Murugaiyan and B. Saha Protumor vs Antitumor Functions of IL-17 J. Immunol., October 1, 2009; 183(7): 4169 - 4175. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu, X. Yuan, M. Xu, F. McLafferty, J. Hu, B. S. Lee, G. Liu, Z. Zeng, K. L. Black, and J. S. Yu Chemokine CXC receptor 4-mediated glioma tumor tracking by bone marrow-derived neural progenitor/stem cells Mol. Cancer Ther., September 1, 2009; 8(9): 2746 - 2753. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Roses, S. Xu, M. Xu, U. Koldovsky, G. Koski, and B. J. Czerniecki Differential Production of IL-23 and IL-12 by Myeloid-Derived Dendritic Cells in Response to TLR Agonists J. Immunol., October 1, 2008; 181(7): 5120 - 5127. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dhodapkar, S. Barbuto, P. Matthews, A. Kukreja, A. Mazumder, D. Vesole, S. Jagannath, and M. V. Dhodapkar Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma Blood, October 1, 2008; 112(7): 2878 - 2885. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bronte Th17 and cancer: friends or foes? Blood, July 15, 2008; 112(2): 214 - 214. [Full Text] [PDF] |
||||
![]() |
P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma Blood, July 15, 2008; 112(2): 362 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wilkie, G. Picco, J. Foster, D. M. Davies, S. Julien, L. Cooper, S. Arif, S. J. Mather, J. Taylor-Papadimitriou, J. M. Burchell, et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor J. Immunol., April 1, 2008; 180(7): 4901 - 4909. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kryczek, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment J. Immunol., June 1, 2007; 178(11): 6730 - 6733. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |